India hospital medicines | Compare the service, not just the purchase price

The sponsor could be a hospital pharmacy leader, procurement director or service-line executive with authority over a defined workflow. Their first decision might be whether a proposed procurement or outpatient-process change deserves a controlled evaluation. The incentive is a clearer account of delivery conditions and costs. A meeting with an interested person would not be presented as a hospital partnership, commissioning mandate or permission to access patient records.

We suggest selecting one non-clinical decision, such as the preparation of a procurement comparison or a handover review for a defined outpatient service. Inputs could include authorised aggregate demand, purchasing records, stock movements and staff effort. The initial output would identify assumptions and dependencies, rather than recommend individual treatment. Local pharmacy and clinical leaders would define the boundary and review any implication for professional practice.

The hospital’s current review method would be the comparator, applied to the same historical sample. We would measure reconciliation accuracy, time to prepare a usable option appraisal and the number of material questions left unresolved. Site-specific factors such as supplier reliability, storage capacity and payment timing would remain visible. A study in one institution would not justify a claim about all Indian hospitals or establish that a UK workflow can transfer unchanged.

An option appraisal should include the cost of changing the process, training people, maintaining source information and resolving exceptions. It should identify who benefits and who carries additional work. We would also ask whether the proposed data extract can be produced consistently without a major integration project. An attractive recurring benefit can disappear if the required reporting is expensive, unreliable or dependent on one person’s informal knowledge.

We would stop if the sponsor lacks authority, the local payment terms are unresolved or the available records cannot answer the selected question. A next phase would need a documented workflow, appropriate local governance and an agreed operational outcome. The commercial proposition would be a bounded evaluation with a clear deliverable. It would not imply an Indian office, a hospital customer, government endorsement or a clinically deployed PHARMORIS system.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.